Terry J Shackleford

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Signaling Pathway

Endoplasmic Reticulum Stress

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Terry J Shackleford, Seethalakshmi Hariharan, Angelina V Vaseva, Karina Alagoa, Maricruz Espinoza, Hemant K Bid, Fuyang Li, Haihong Zhong, Doris A Phelps, Ryan D Roberts, Hakan Cam, Cheryl A London, Denis C Guttridge, Yidong Chen, Manjeet K Rao, Yuzuru Shiio, Peter J Houghton
Redundant Signaling as the Predominant mechanism for Resistance to Antibodies Targeting IGF-1R in Cells Derived from Childhood Sarcoma. Molecular cancer therapeutics (2023)
Terry J Shackleford, Seethalakshmi Hariharan, Angelina V Vaseva, Karina Alagoa, Maricruz Espinoza, Hemant K Bid, Fuyang Li, Haihong Zhong, Doris A Phelps, Ryan D Roberts, Hakan Cam, Cheryl A London, Denis C Guttridge, Yidong Chen, Manjeet K Rao, Yuzuru Shiio, Peter J Houghton
Redundant Signaling as the Predominant mechanism for Resistance to Antibodies Targeting IGF-1R in Cells Derived from Childhood Sarcoma. Molecular cancer therapeutics (2023)
Terry J Shackleford, Seethalakshmi Hariharan, Angelina V Vaseva, Karina Alagoa, Maricruz Espinoza, Hemant K Bid, Fuyang Li, Haihong Zhong, Doris A Phelps, Ryan D Roberts, Hakan Cam, Cheryl A London, Denis C Guttridge, Yidong Chen, Manjeet K Rao, Yuzuru Shiio, Peter J Houghton
Redundant Signaling as the Predominant mechanism for Resistance to Antibodies Targeting IGF-1R in Cells Derived from Childhood Sarcoma. Molecular cancer therapeutics (2023)
Natalia Garcia, Vanessa Del Pozo, Marielle E Yohe, Craig M Goodwin, Terry J Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T Rogojina, Sara M Zimmerman, Cody J Peer, William Douglas Figg, Myron S Ignatius, Kris C Wood, Peter J Houghton, Angelina V Vaseva
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma. Molecular cancer therapeutics (2021)